Pacific Biosciences is trading up 10.05% at $2.02 on October 20, with the rally linked to its October 19 multi-year collaboration with Verily Health. - The companies will combine HiFi sequencing with Verily’s data and AI platform to create AI-ready genomic and clinical datasets. - Shares gained 6.36% in the previous session. The agreement has no disclosed financial terms, leaving the scale of any commercial impact uncertain.